{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-25-000011","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.308472+00:00","generated_at":"2026-05-26T01:15:17.562224+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Altimmune posts Q4 net loss $23.2M; CMO to retire; pemvidutide MASH data on track","bullets":["Net loss Q4 2024 $23.2M ($0.33/share) vs $31.6M in Q4 2023 (incl $12.4M impairment); FY2024 net loss $95.1M ($1.34/share).","Cash, cash equivalents and short-term investments $131.9M at Dec 31, 2024.","CMO Dr. Scott Harris will retire effective Feb 28, 2026; company to search for successor.","Top-line data from Phase 2b IMPACT MASH trial expected Q2 2025; IND cleared for two additional indications with Phase 2 trials mid-2025.","Board adds Teri Lawver (ex-Dexcom, J&J) and Jerry Durso (ex-Intercept CEO, Sanofi)."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-25-000011","json":"https://secwatch.observer/filing/0001326190-25-000011.json","markdown":"https://secwatch.observer/filing/0001326190-25-000011.md","text":"https://secwatch.observer/filing/0001326190-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000011/0001326190-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000011/alt-20250224x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:15:17.562224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03de39d838","claim":"Scott Harris departed as Chief Medical Officer at Altimmune, Inc..","evidence_excerpt":"On February 24, 2025, the Company’s Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000011/0001326190-25-000011-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}